We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AVROBIO Inc | NASDAQ:AVRO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.81% | 1.22 | 1.13 | 1.30 | 1.24 | 1.18 | 1.23 | 202,097 | 05:00:07 |
From May 2023 to May 2024
By Sabela Ojea
Shares of Avrobio on Thursday climbed 16% to 67 cents in pre-market trading Thursday after the company provided positive data from its phase 1/2 clinical trial evaluating a cystinosis gene therapy treatment.
The Cambridge, Mass.-based clinical-stage gene therapy company said the cystinosis program has also received positive regulatory feedback in meetings with the U.S. Food and Drug Administration and U.K. Medicines and Healthcare products Regulatory Agency.
"We are excited about moving this investigational gene therapy closer to patients," said Chief Medical Officer Essra Ridha.
Cystinosis is a rare genetic disorder characterized by the accumulation of an amino acid in different tissues and organs of the body.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 18, 2023 07:59 ET (11:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AVROBIO Chart |
1 Month AVROBIO Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
